U. S. NIH to finance Samjin viral new compound.

A new anti-viral agent developed by Samjin for the treatment of HIV, an AIDS virus, has been found of its excellent efficacy, and now Samjin may receive a financial support from the U. S. NIH for the development of an innovative topical cocktail therapy.

In close association with ImQuest, a U. S. company, Samjin has succeeded to develop not only conventional simple topical drug but also a c...